fda warning letters glp-1 compounding september 26 2025 Diabetes advocacy group discourages use of compounded drugs FDA issued 25 warning letters

$99/first month Applies to 3-month plan billed in full ($149/mo after) Whats included Personalized, clinician-guided plan Monthly and 3-month plans Dispensed by US-licensed compounding pharmacy Unlimited protocol adjustments and messaging Ongoing support and check-ins Pause or cancel anytime Backed by our in-house Stanford PhD-led team Get Started Made for your biology No two people age the same way, so no two treatments are exactly the same

Trials of semaglutide (SUSTAIN-1 and STEP 1) report 46 kg and up to 15% body weight loss, respectively ( Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) )

No head-to-head trials between Foundayo and oral Wegovy have been conducted to date

And if something goes wrong, there is a clear regulatory pathway for accountability

And a strong dietary GLP-1 stimulus might be able to do both

We are committed to confronting the stigma linked with chronic diseases, like obesity, and expanding access to our authentic, prescription-only medicines. For more on weight management: Hims & Hers Super Bowl ad slams pricey pharma industryand fumbles FDA warnings on compounded GLP-1 drugs Exclusive: The COO of Hims & Hers was the third person to try its new weight-loss drugsand shes ready to share her story Online searches predicted the surge in prescriptions of weight-loss drugs like Wegovy and Zepbound, study says